Women's Health

Medically reviewed by Dr. Sarah Collins, MPharm, AHPRA Registered Pharmacist — Updated April 2026

Women's Health Products — Australia

Women's health encompasses a wide spectrum of therapeutic needs that are frequently underserved by mainstream healthcare — from sexual health and fertility support to cosmetic concerns including eyelash growth and glaucoma management. At redstonerx-au.com we offer a carefully selected range of women's health products covering four key categories: female sexual health (Lovegra), eyelash growth and eye pressure management (Careprost, Bimat, Lumigan), and female fertility support (Clomid). All products are sourced from WHO-GMP certified manufacturers and delivered discreetly to all Australian states and territories in 4 to 9 business days. All product information has been medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist.

Our Women's Health Products — Overview

Lovegra (Women's Viagra) — Female Sexual Arousal Disorder

Lovegra contains sildenafil citrate 100mg — the same PDE5 inhibitor active ingredient as Viagra, formulated for women experiencing female sexual arousal disorder (FSAD) and related conditions. Lovegra works by increasing blood flow to genital tissue — enhancing clitoral engorgement, vaginal lubrication, and tactile sensitivity during sexual stimulation. The strongest clinical evidence for sildenafil in women comes from studies of SSRI/SNRI antidepressant-induced sexual dysfunction — a common and distressing side effect affecting Australian women on antidepressants for depression and anxiety disorders. Sildenafil does not increase sexual desire (libido) — it addresses the physiological genital arousal response.

Who benefits most from Lovegra in Australia:

• Women experiencing reduced genital arousal, lubrication difficulties, or orgasmic dysfunction as a side effect of SSRI or SNRI antidepressants (fluoxetine/Prozac, sertraline/Zoloft, venlafaxine/Effexor, escitalopram/Lexapro) — extremely common in Australia where antidepressant prescription rates are among the highest in the world
• Post-menopausal women with physiological female sexual arousal disorder — declining oestrogen levels reduce genital blood flow and tissue sensitivity
• Women with diabetes-related sexual dysfunction — vascular and neurological changes impair genital arousal analogously to male diabetic erectile dysfunction
• Women who have noticed reduced arousal, lubrication difficulties, or reduced sensitivity compared to previous experience

Lovegra is not suitable for: Women whose primary concern is low sexual desire (libido) without genital arousal difficulties — sildenafil addresses peripheral vascular response, not central desire pathways. For low libido, speak with a sexual health clinician.

TGA status: Lovegra is not TGA-registered as a specific product in Australia. Personal importation for personal therapeutic use is permitted under the TGA Personal Importation Scheme (Section 19(1) Therapeutic Goods Act 1989) for up to a 3-month supply. Consultation with an Australian GP or sexual health clinician is recommended before use.

Careprost & Bimat — Eyelash Growth (Bimatoprost 0.03%)

Careprost and Bimat both contain bimatoprost 0.03% — a prostaglandin F2α analogue originally developed for glaucoma management that was found to produce remarkable eyelash growth as a side effect. This led to the development of Latisse (bimatoprost 0.03% for lashes) by Allergan — approved by the US FDA for eyelash hypotrichosis (inadequate eyelashes). Careprost (Sun Pharmaceutical) and Bimat are generic equivalents of Latisse at a fraction of the price.

Clinical results with bimatoprost eyelash treatment: Clinical trials conducted by Allergan (the original Latisse/Lumigan developer) demonstrated that bimatoprost 0.03% applied nightly to the upper lash line produces statistically significant increases in eyelash length (+25%), thickness/fullness (+106%), and darkness (+18%) compared to baseline after 16 weeks of use. Results are maintained with continued use and partially reverse within weeks of discontinuation.

How to use Careprost/Bimat for eyelash growth:

• Apply one drop to the applicator brush (included) or a clean eyeliner brush
• Apply along the base of the upper eyelashes only — like applying eyeliner, from inner to outer corner
• Do not apply to lower lashes directly — product will naturally migrate
• Apply nightly before bed after removing make-up and contact lenses
• Wait 15 minutes before reinserting contact lenses (benzalkonium chloride preservative)
• Wipe away any excess with a tissue — do not allow product to run onto skin below eye
• Results typically visible from 4 to 6 weeks; full results at 12 to 16 weeks
• Once desired result achieved, reduce to 2–3 times per week maintenance

Careprost vs Bimat vs Lumigan — what's the difference: All three contain bimatoprost 0.03% and are therapeutically equivalent for eyelash growth. Careprost is manufactured by Sun Pharmaceutical (BSE/NYSE: SUNP — India's largest pharma company). Bimat is another Sun Pharma formulation. Lumigan is the Allergan brand (now AbbVie) — the original prescription glaucoma drop that also treats intraocular pressure. Lumigan is typically the most expensive as it is the branded originator product.

Important safety notes for Careprost/Bimat: Bimatoprost can cause increased brown pigmentation of the iris (permanent) if it enters the eye — this is why application to the upper lash line only (not directly into the eye) is critical. Bimatoprost can also cause darkening of eyelid skin — usually reversible. Individuals with green or hazel eyes using bimatoprost near the eye should be aware of this iris pigmentation risk.

Lumigan (Bimatoprost 0.03%) — Glaucoma and Eyelash Growth

Lumigan (bimatoprost ophthalmic solution 0.03%) is Allergan's original brand for the ophthalmic prostaglandin analogue. It has two clinical applications:

1. Glaucoma and ocular hypertension — primary TGA-registered indication: Lumigan reduces intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. It works by increasing aqueous humour outflow through both the trabecular meshwork and uveoscleral pathways. Applied as one drop to the affected eye(s) once nightly. In clinical trials, Lumigan reduced IOP by approximately 8–9 mmHg from baseline — one of the most effective single agents for IOP reduction, superior to timolol beta-blocker drops in many studies.

2. Eyelash growth (off-label in Australia): Applied to the upper lash line nightly for cosmetic eyelash growth — the same mechanism and results as Careprost/Bimat but at a higher price point as the branded originator product.

Who should consider Lumigan over Careprost/Bimat: Patients already using Lumigan for medically-prescribed glaucoma management, or those who specifically prefer the Allergan brand. For cosmetic eyelash growth purposes, Careprost and Bimat offer identical bimatoprost 0.03% at significantly lower cost.

Clomid Generic (Clomiphene Citrate) — Ovulation Induction and Female Fertility

Clomid Generic contains clomiphene citrate — a selective oestrogen receptor modulator (SERM) that has been the first-line pharmacological treatment for anovulatory infertility (failure to ovulate) for over 50 years. Clomiphene is listed on the Australian PBS (Pharmaceutical Benefits Scheme) for ovulation induction in women with anovulation — making it one of the few fertility medications with PBS subsidy in Australia.

How clomiphene works — ovulation induction: Clomiphene binds competitively to oestrogen receptors in the hypothalamus — blocking the normal oestrogen negative feedback. The hypothalamus perceives a low-oestrogen state and increases GnRH pulse frequency, which increases FSH (follicle-stimulating hormone) and LH (luteinising hormone) release from the pituitary. Elevated FSH stimulates follicular development in the ovaries. One or more follicles mature and — triggered by the LH surge — ovulate. This restores or induces ovulation in women who are not ovulating naturally.

Primary Australian indications for clomiphene:

• Polycystic Ovary Syndrome (PCOS) — most common use in Australia: PCOS affects approximately 1 in 10 Australian women of reproductive age and is the most common cause of anovulatory infertility. Clomiphene is the first-line ovulation induction agent in PCOS per Fertility Society of Australia (FSA) guidelines — achieving ovulation in 70–85% of women and pregnancy in approximately 30–40% after 6 cycles
• Hypothalamic amenorrhoea: Absent periods due to hypothalamic dysfunction (including exercise-associated amenorrhoea, weight-related amenorrhoea)
• Unexplained infertility with ovulatory cycles: Clomiphene with timed intercourse or intrauterine insemination (IUI) — though letrozole has largely replaced clomiphene for this indication in Australian fertility clinics
• Luteal phase defect: Improving follicular development and consequent progesterone production in the luteal phase

Clomiphene dosing protocol — standard Australian approach:

• Start on Day 2, 3, 4, or 5 of the menstrual cycle (Day 2 or 3 most common in Australia)
• Standard starting dose: 50mg daily for 5 consecutive days
• Ovulation typically occurs 5 to 10 days after the last clomiphene tablet — around Day 14–19 of the cycle
• If no ovulation at 50mg after 2 cycles, dose increased to 100mg. If no ovulation at 100mg, 150mg may be tried
• Maximum recommended duration: 6 ovulatory cycles at the minimum effective dose. Beyond 6 cycles, risk-benefit must be reassessed with a fertility specialist
• Monitoring: Ultrasound follicle tracking (transvaginal ultrasound) from Day 10–12 to confirm follicular development and predict ovulation timing — strongly recommended when starting clomiphene, particularly in Australia where fertility monitoring is accessible

Important Australian context — clomiphene vs letrozole for PCOS: A landmark RCT (Legro et al., NEJM 2014) and subsequent Australian fertility society guidance have established letrozole (Femara — an aromatase inhibitor) as superior to clomiphene for ovulation induction in women with PCOS — higher live birth rates, lower multiple pregnancy rates. However, clomiphene remains widely used in Australia, is PBS-listed, is significantly less expensive, and is appropriate for many women with anovulatory infertility. Discuss with your fertility specialist which agent is most appropriate for your specific situation.

Multiple pregnancy risk: Clomiphene carries an approximately 8–10% risk of twin pregnancy (vs 1% background rate) and a small risk of higher-order multiples — due to stimulation of multiple follicle development. Ultrasound monitoring is essential to identify over-response (more than 2–3 mature follicles) and allow cycle cancellation if necessary to reduce multiple pregnancy risk.

Women's Health in Australia — The Treatment Gap

Australian women face a significant treatment gap in several areas of women's health:

• Female sexual dysfunction: Despite affecting 40–45% of Australian women, approved pharmacological treatments for female sexual dysfunction remain extremely limited in Australia. The TGA has not approved flibanserin (Addyi) or bremelanotide (Vyleesi) — both US FDA-approved for hypoactive sexual desire disorder — leaving Australian women with limited options. Sildenafil (Lovegra) used off-label fills part of this gap for women with physiological arousal disorder
• Fertility: IVF waiting times in the public system in Australia can be lengthy. Clomiphene provides an accessible, relatively low-cost first-line option for ovulation induction that can be initiated by a GP (with appropriate monitoring) before specialist fertility referral is necessary
• Eyelash hypotrichosis: Latisse (bimatoprost for eyelashes) is not PBS-listed and is expensive at Australian retail prices. Careprost and Bimat provide the identical active ingredient at significantly lower cost

Delivery to All Australian States and Territories

redstonerx-au.com ships all women's health products discreetly to all Australian states and territories. Standard delivery: 4–9 business days.

New South Wales (Sydney, Newcastle, Wollongong, Central Coast) — Victoria (Melbourne, Geelong, Ballarat, Bendigo) — Queensland (Brisbane, Gold Coast, Sunshine Coast, Cairns, Townsville) — Western Australia (Perth, Fremantle, Bunbury, Mandurah) — South Australia (Adelaide, Mount Gambier, Whyalla) — Tasmania (Hobart, Launceston, Devonport) — Australian Capital Territory (Canberra) — Northern Territory (Darwin, Alice Springs).

All orders are dispatched in plain, unmarked packaging with no reference to the contents or sender. A tracking number is provided with every order.

Frequently Asked Questions — Women's Health Products in Australia

Is it legal to order women's health products from redstonerx-au.com in Australia? The TGA's Personal Importation Scheme permits Australian residents to import up to a 3-month personal supply of therapeutic goods not registered in Australia for personal therapeutic use (Section 19(1) Therapeutic Goods Act 1989). Products must be for your own use and not for supply to others. Clomid generic (clomiphene) and sildenafil are Schedule 4 prescription medicines in Australian pharmacies — personal importation represents a legal grey area. We strongly recommend consulting an Australian GP or specialist before ordering any prescription-category product.

Which products are best for eyelash growth? Careprost, Bimat, and Lumigan all contain bimatoprost 0.03% and are equally effective for eyelash growth. Clinical trials demonstrate +25% longer, +106% thicker, and +18% darker lashes after 16 weeks of nightly use. Careprost and Bimat are significantly more affordable than Lumigan (Allergan brand). For cost-effective eyelash treatment, Careprost or Bimat are the practical choice.

Do I need a prescription for Clomid (clomiphene) in Australia? In Australian pharmacies, clomiphene is a Schedule 4 prescription medicine requiring a valid Australian prescription. The TGA Personal Importation Scheme permits personal imports for personal therapeutic use. We strongly recommend working with an Australian fertility specialist or GP when using clomiphene — ultrasound monitoring of follicular response is important for safety and effectiveness, and clomiphene is PBS-listed (subsidised) when prescribed by an Australian doctor.

Will Lovegra increase my sex drive? No — Lovegra (sildenafil) addresses the physiological genital arousal response (blood flow, lubrication, engorgement) but does not affect sexual desire or libido. If low desire is your primary concern, sildenafil is unlikely to help. Sexual desire issues are best addressed with a sexual health clinician who can provide appropriate treatment options.

How long does delivery to Australia take? Standard delivery to all Australian states and territories takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

All information on this page is for general informational purposes only and does not constitute medical advice. Always consult a qualified Australian healthcare provider before starting any new medication or therapeutic product.